Abstract
Dacomitinib is a second-generation EGFR tyrosine kinase inhibitor (TKI) that irreversibly binds to and inhibits EGFR/Her1, Her2 and Her4 subtypes with an efficacy comparable to other TKIs. In the ARCHER 1050 trial, progression-free survival was improved by dacomitinib compared with gefitinib, supporting dacomitinib as a first-line treatment option for advanced non-small-cell lung cancer with sensitive EGFR mutation. Regarding to the higher adverse events rate, dose reductions did not reduce the efficacy of dacomitinib and could effectively decreased the incidence and severity of adverse events. Considering the evolving landscape of EGFR-mutant non-small-cell lung cancer, future head to head comparison between dacomitinib and osimertinib could provide key information to determine the optimal TKI treatment schedule.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129–2139 (2004).
- 2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497–1500 (2004).
- 3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239–246 (2012).
- 4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12(8), 735–742 (2011).
- 5. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362(25), 2380–2388 (2010).
- 6. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947–957 (2009).
- 7. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 7(7), 1880–1889 (2008).
- 8. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 67(24), 11924–11932 (2007).
- 9. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, Phase 3 trial. Lancet Oncol. 18(11), 1454–1466 (2017). •• An important study demonstrates that dacomitinib is superior to gefitinib respect to progression-free survival and response rate in the first-line therapy of EGFR mutation non-small-cell lung cancer (NSCLC).
- 10. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J. Clin. Oncol. 36(22), 2244–2250 (2018). •• The Following analysis of ARCHER 1050 which demonstrate dacomitinib can bring a longer overal survival than gefitinib as first-line therapy for EGFR mutation NSCLC.
- 11. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 10(1), 25–38 (2006).
- 12. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J. Clin. Oncol. 25(16), 2248–2255 (2007).
- 13. Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma. Mol. Cancer Ther. 14(7), 1548–1558 (2015).
- 14. Second-line treatment of non-small cell lung cancer: focus on the clinical development of dacomitinib. Front. Med. 4(8), 947–945 (2017).
- 15. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, Phase 3 trial. Lancet Oncol. 15(12), 1369–1378 (2014).
- 16. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, Phase 3 trial. Lancet Oncol. 15(12), 1379–1388 (2014).
- 17. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin. Cancer Res. 18(18), 4910–4918 (2012).
- 18. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2(10), 922–933 (2012).
- 19. Targeting HER2 aberrations as actionable drivers in lung cancers: Phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann. Oncol. 26(7), 1421–1427 (2015).
- 20. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin. Cancer Res. 17(5), 1131–1139 (2011).
- 21. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, Phase 2 trial. Lancet Oncol. 15(13), 1433–1441 (2014). • This single-arm ARCHER 1017 trial first supported that dacomitinib can bring a promising progression-free survival (18.2 months) for untreated NSCLC harboring EGFR-mutant non-small-lung cancer.
- 22. . Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. Lung Cancer. 82(2), 313–318 (2013).
- 23. . A neuro-oncologist's perspective on management of brain metastases in patients with EGFR mutant non-small cell lung cancer. Curr. Treat. Options in Oncol. 18(4), 22 (2017).
- 24. . Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer. Front. Oncol. 8, 59950 (2018).
- 25. . ARCHER 1050: hitting an important mark in EGFR-mutant lung cancer? J. Clin. Oncol. 36(22), 2241–2243 (2018).
- 26. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31(27), 3327–3334 (2013).
- 27. A Phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 120(8), 1145–1154 (2014).
- 28. A Phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Ann. Oncol. 27(9), 1712–1718 (2016).
- 29. Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive NSCLC. J. Thorac. Oncol. 13(10), S454 (2018).
- 30. . Dose-limiting toxicity and maximum tolerated dose: still fit for purpose? Lancet Oncol. 16(13), 1287–1288 (2015).
- 31. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clinical Cancer Research. 16(4), 1289–1297 (2010).
- 32. . Trends in the use and role of biomarkers in Phase I oncology trials. Clinical Cancer Research. 13(22 Pt 1), 6719–6726 (2007).
- 33. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J. Clin. Oncol. 30(23), 2861–2868 (2012).
- 34. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378(2), 113–125 (2018). •• An important clinical trial which indicated that osimertinib is superior to first-generation TKI (gefitinib) regarding to PFS.
- 35. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a Phase 2B, open-label, randomised controlled trial. Lancet Oncol. 17(5), 577–589 (2016). • A study compared the efficacy of afatinib and gefitinib as first-line treatment for advanced NSCLC